Stock Market Dailies: Teva Pharma Industries, Dynavax Technologies, Covidien, and Valeant Pharma Intl.
LONDON, December 11, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, December 10, 2013, the U.S. equity market finished on a negative note. The S&P 500 ended the day at 1,802.62, down 0.32%; the Dow Jones Industrial Average closed at 15,973.13, down 0.33%; and the NASDAQ Composite finished at 4,060.49, down 0.20%. The S&P 500 Health Care Sector Index edged 0.43% lower to close at 636.17; the same has gained 8.40% in the previous three months and 3.40% in the last one month, outperforming the S&P 500, which has gained 7.04% and 1.81% during the respective periods. The major movers in the sector included Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Dynavax Technologies Corp. (NASDAQ: DVAX), Covidien PLC (NYSE: COV), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). AAAResearchReports.com initiated preliminary technical research on TEVA, DVAX, COV, and VRX. These free reports are accessible by signing today at:
Teva Pharmaceutical Industries Ltd's stock surged 2.19% on Tuesday, even as the US equity market edged lower. The company's shares ended the day at $41.03, after vacillating between $40.06 and $41.45 during the trading session. A total of 14.59 million shares were traded, which is above the daily average volume of 5.87 million. The company's shares have gained 10.09% in the previous one month and 7.83% in the last three months, outperforming the S&P 500, which has advanced 1.81% and 7.04% during the respective periods. Further, Teva Pharmaceutical Industries Ltd's stock is trading above its 50-day and 200-day moving averages of $39.21 and $39.10, respectively. The free technical analysis on TEVA is available by signing up at:
Shares in Dynavax Technologies Corp. plummeted 2.37% on Tuesday, closing the day at $1.65, after oscillating between $1.63 and $1.71 during the trading session. A total of 2.68 million shares were traded, which is below the daily average volume of 3.86 million. Despite Tuesday' decline, the company's shares have rallied 38.66% in the previous three months and 42.24% in the last one month, outperforming the S&P 500, which has advanced 7.04% and 1.81% during the respective periods. Moreover, Dynavax Technologies Corp.'s stock is trading above its 50-day and 200-day moving averages of $1.35 and $1.64, respectively. Register now to download free research on DVAX at:
Covidien PLC's stock edged lower on Tuesday, finishing the day 0.48% lower at $67.80, after vacillating between $67.61 and $68.14 during the trading session. A total of 1.75 million shares were traded, which is below the daily average volume of 2.13 million. Despite Tuesday's pullback, the company's shares have gained 10.19% in the previous three months and 6.20% in the last one month, outperforming the S&P 500, which has gained 7.04% and 1.81% during the respective periods. Furthermore, Covidien PLC's stock is trading above its 50-day and 200-day moving averages of $64.40 and $61.14, respectively. A free report on COV can be accessed by registering at:
On Tuesday, Valeant Pharmaceuticals International Inc.'s stock posted gains to end the day at $108.62, which is 0.60% higher than the previous day's closing price of $107.97. The company's shares vacillated between $107.78 and $108.83 during the trading session. A total of 1.02 million shares were traded, which is below the daily average volume of 1.11 million. The company's shares have gained 3.02% in the previous one month and 8.40% in the last three months, outperforming the S&P 500, which has gained 1.81% and 7.04% during the respective periods. Additionally, Valeant Pharmaceuticals International Inc.'s stock is trading above its 200-day moving average of $91.22. Register with AAA Research Reports and download research on VRX for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports